Genedrive : Grant of options

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

genedrive plc (LSE: GDR) ('genedrive' or the 'Company'), the near patient molecular diagnostics company, announces that it has granted share options ('Options') to members of its senior management team to acquire a total of 2,169,608 ordinary shares of 1.5p each ('Ordinary Shares') in the Company under the Company's Share Option Scheme.

The Options have been granted with an exercise price equal to the close price on the day before the grant and vest after a period of three years, subject to certain performance criteria being met through achieving revenue targets, achieving cash targets and completing certain strategic projects in the year ending June 2022. The Options are exercisable over the period of 10 years from the date of grant.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	1. David Budd 2. Matthew Fowler 3. Gino Miele 4. Gordon Powell 5. Colleen Pythian
2.	Reason for the notification
a.	Position/status	1. CEO 2. CFO 3. R&D Director 4. Commercial Director 5. Director of Quality & Regulation
a.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	genedrive plc
b.	LEI	213800ZYODIRZ87Y4K14
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Options over ordinary shares of 1.5 pence each GB00B1VKB244
b.	Nature of the transaction	Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 29 November 2017
c.	Price(s) and volume(s)	Option price(s) Volume(s) David Budd 9.0p 1,056,982 Matthew Fowler 9.0p 672,626 Gino Miele 9.0p 170,000 Gordon Powell 9.0p 170,000 Colleen Pythian 9.0p 100,000
d.	Aggregated information · Aggregated volume · Price	N/A
e.	Date of the transaction	2020-04-03
f.	Place of the transaction	Outside a trading venue

For further details please contact:

genedrive plc	[phone]
David Budd: CEO / Matthew Fowler: CFO
Peel Hunt LLP (Nominated Adviser and Joint Broker)	[phone]
James Steel / Oliver Jackson
Stanford Capital Partners Limited (Joint Broker)	[phone]
Patrick Claridge / John Howes
Walbrook PR Ltd (Media Relations & Investor Relations)	[phone] [e-mail]
Paul McManus / Anna Dunphy	[phone] / [phone]